JP4386971B2 - スプライシング配列を含んでなる組換えアデノウイルスベクター - Google Patents

スプライシング配列を含んでなる組換えアデノウイルスベクター Download PDF

Info

Publication number: JP4386971B2
Authority: JP; Japan
Prior art keywords: gene; adenoviral vector; sequence; vector; expression
Prior art date: 1997-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP50171699A

Other languages

English (en)

Japanese (ja)

Other versions

JP2002511751A (ja

Inventor

マジド、メタリ

ピエール、レロワ

アン−イザベル、ミシュー

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Transgene SA

Original Assignee

Transgene SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-02

Filing date

1998-06-02

Publication date

2009-12-16

1998-06-02 Application filed by Transgene SA filed Critical Transgene SA

2002-04-16 Publication of JP2002511751A publication Critical patent/JP2002511751A/ja

2009-12-16 Application granted granted Critical

2009-12-16 Publication of JP4386971B2 publication Critical patent/JP4386971B2/ja

2018-06-02 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000013598 vector Substances 0.000 title claims abstract description 116
108090000623 proteins and genes Proteins 0.000 claims abstract description 83
230000014509 gene expression Effects 0.000 claims abstract description 47
241000701161 unidentified adenovirus Species 0.000 claims abstract description 38
208000015181 infectious disease Diseases 0.000 claims abstract description 32
239000002245 particle Substances 0.000 claims abstract description 27
230000003612 virological effect Effects 0.000 claims abstract description 27
230000002458 infectious effect Effects 0.000 claims abstract description 20
238000000034 method Methods 0.000 claims abstract description 18
230000001225 therapeutic effect Effects 0.000 claims abstract description 15
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
230000000069 prophylactic effect Effects 0.000 claims abstract description 5
241000700605 Viruses Species 0.000 claims description 23
239000002299 complementary DNA Substances 0.000 claims description 19
239000012634 fragment Substances 0.000 claims description 15
102000004196 processed proteins & peptides Human genes 0.000 claims description 14
108090000765 processed proteins & peptides Proteins 0.000 claims description 14
229920001184 polypeptide Polymers 0.000 claims description 13
241000701022 Cytomegalovirus Species 0.000 claims description 12
241000282414 Homo sapiens Species 0.000 claims description 12
108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 11
230000000295 complement effect Effects 0.000 claims description 11
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 10
241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
238000001415 gene therapy Methods 0.000 claims description 8
241001465754 Metazoa Species 0.000 claims description 7
241000714474 Rous sarcoma virus Species 0.000 claims description 7
239000000203 mixture Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 5
101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
230000035772 mutation Effects 0.000 claims description 5
238000012258 culturing Methods 0.000 claims description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
230000008488 polyadenylation Effects 0.000 claims description 4
108020005544 Antisense RNA Proteins 0.000 claims description 3
241000271566 Aves Species 0.000 claims description 3
241000283690 Bos taurus Species 0.000 claims description 3
102000053642 Catalytic RNA Human genes 0.000 claims description 3
108090000994 Catalytic RNA Proteins 0.000 claims description 3
241000282693 Cercopithecidae Species 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
241001529936 Murinae Species 0.000 claims description 3
239000003184 complementary RNA Substances 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
108020003175 receptors Proteins 0.000 claims description 3
108091092562 ribozyme Proteins 0.000 claims description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
102000004127 Cytokines Human genes 0.000 claims description 2
102000001039 Dystrophin Human genes 0.000 claims description 2
108010069091 Dystrophin Proteins 0.000 claims description 2
102000004190 Enzymes Human genes 0.000 claims description 2
108090000790 Enzymes Proteins 0.000 claims description 2
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 claims description 2
108090001061 Insulin Proteins 0.000 claims description 2
241001494479 Pecora Species 0.000 claims description 2
239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
239000003114 blood coagulation factor Substances 0.000 claims description 2
238000004113 cell culture Methods 0.000 claims description 2
239000002532 enzyme inhibitor Substances 0.000 claims description 2
229940125532 enzyme inhibitor Drugs 0.000 claims description 2
239000003102 growth factor Substances 0.000 claims description 2
239000002596 immunotoxin Substances 0.000 claims description 2
231100000608 immunotoxin Toxicity 0.000 claims description 2
230000002637 immunotoxin Effects 0.000 claims description 2
229940051026 immunotoxin Drugs 0.000 claims description 2
229940125396 insulin Drugs 0.000 claims description 2
239000003446 ligand Substances 0.000 claims description 2
230000017105 transposition Effects 0.000 claims description 2
239000013603 viral vector Substances 0.000 claims 3
238000002360 preparation method Methods 0.000 claims 2
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
241000894006 Bacteria Species 0.000 claims 1
102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims 1
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 1
208000031886 HIV Infections Diseases 0.000 claims 1
208000037357 HIV infectious disease Diseases 0.000 claims 1
108700005091 Immunoglobulin Genes Proteins 0.000 claims 1
102000004877 Insulin Human genes 0.000 claims 1
241000009328 Perro Species 0.000 claims 1
230000001093 anti-cancer Effects 0.000 claims 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
230000002401 inhibitory effect Effects 0.000 claims 1
244000045947 parasite Species 0.000 claims 1
239000003053 toxin Substances 0.000 claims 1
231100000765 toxin Toxicity 0.000 claims 1
108700012359 toxins Proteins 0.000 claims 1
108010054218 Factor VIII Proteins 0.000 abstract description 5
102000001690 Factor VIII Human genes 0.000 abstract description 5
229960000301 factor viii Drugs 0.000 abstract description 5
-1 beta or beta-globine Proteins 0.000 abstract description 4
102000008186 Collagen Human genes 0.000 abstract description 3
108010035532 Collagen Proteins 0.000 abstract description 3
229920001436 collagen Polymers 0.000 abstract description 3
241000124008 Mammalia Species 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 68
102100022641 Coagulation factor IX Human genes 0.000 description 14
108010076282 Factor IX Proteins 0.000 description 14
206010028980 Neoplasm Diseases 0.000 description 14
229960004222 factor ix Drugs 0.000 description 14
238000012217 deletion Methods 0.000 description 11
230000037430 deletion Effects 0.000 description 11
210000002845 virion Anatomy 0.000 description 11
108010002350 Interleukin-2 Proteins 0.000 description 10
102000000588 Interleukin-2 Human genes 0.000 description 10
241000282465 Canis Species 0.000 description 8
108091092195 Intron Proteins 0.000 description 7
238000002744 homologous recombination Methods 0.000 description 7
230000006801 homologous recombination Effects 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 6
230000003321 amplification Effects 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
230000002950 deficient Effects 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
108700024394 Exon Proteins 0.000 description 5
238000010367 cloning Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
108020004707 nucleic acids Proteins 0.000 description 5
102000039446 nucleic acids Human genes 0.000 description 5
150000007523 nucleic acids Chemical class 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
238000003752 polymerase chain reaction Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
239000013589 supplement Substances 0.000 description 5
102100021519 Hemoglobin subunit beta Human genes 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
201000003883 Cystic fibrosis Diseases 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
238000010276 construction Methods 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000000644 propagated effect Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
238000010361 transduction Methods 0.000 description 3
230000026683 transduction Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
108010052875 Adenine deaminase Proteins 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000052510 DNA-Binding Proteins Human genes 0.000 description 2
101710096438 DNA-binding protein Proteins 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
108091005902 Hemoglobin subunit alpha Proteins 0.000 description 2
102100027685 Hemoglobin subunit alpha Human genes 0.000 description 2
208000031220 Hemophilia Diseases 0.000 description 2
208000009292 Hemophilia A Diseases 0.000 description 2
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
208000026350 Inborn Genetic disease Diseases 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
108010008707 Mucin-1 Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
208000029578 Muscle disease Diseases 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 2
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
208000029742 colonic neoplasm Diseases 0.000 description 2
231100000433 cytotoxic Toxicity 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
230000004927 fusion Effects 0.000 description 2
208000016361 genetic disease Diseases 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000002601 intratumoral effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000003098 myoblast Anatomy 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
229950010131 puromycin Drugs 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
230000007017 scission Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
102100022987 Angiogenin Human genes 0.000 description 1
102400000068 Angiostatin Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
102000007592 Apolipoproteins Human genes 0.000 description 1
108010071619 Apolipoproteins Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
101150017888 Bcl2 gene Proteins 0.000 description 1
101150008012 Bcl2l1 gene Proteins 0.000 description 1
101150104494 CAV1 gene Proteins 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102100035882 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
101150047856 Cav2 gene Proteins 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102100026735 Coagulation factor VIII Human genes 0.000 description 1
102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
101150074155 DHFR gene Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
108010079505 Endostatins Proteins 0.000 description 1
101710145505 Fiber protein Proteins 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
101000807008 Homo sapiens Uracil phosphoribosyltransferase homolog Proteins 0.000 description 1
241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000003814 Interleukin-10 Human genes 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010025815 Kanamycin Kinase Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
241001045988 Neogene Species 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010077971 Plasminogen Inactivators Proteins 0.000 description 1
102000010752 Plasminogen Inactivators Human genes 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
208000000236 Prostatic Neoplasms Diseases 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
102000009572 RNA Polymerase II Human genes 0.000 description 1
108010009460 RNA Polymerase II Proteins 0.000 description 1
108090000783 Renin Proteins 0.000 description 1
102100028255 Renin Human genes 0.000 description 1
241001068295 Replication defective viruses Species 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
101100502554 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FCY1 gene Proteins 0.000 description 1
101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101150003725 TK gene Proteins 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
102000018252 Tumor Protein p73 Human genes 0.000 description 1
108010091356 Tumor Protein p73 Proteins 0.000 description 1
102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
108060008724 Tyrosinase Proteins 0.000 description 1
102100037717 Uracil phosphoribosyltransferase homolog Human genes 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
108020002494 acetyltransferase Proteins 0.000 description 1
102000005421 acetyltransferase Human genes 0.000 description 1
208000037919 acquired disease Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
108010072788 angiogenin Proteins 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
108700000707 bcl-2-Associated X Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000000408 embryogenic effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229940126864 fibroblast growth factor Drugs 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
108060003196 globin Proteins 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
102000057593 human F8 Human genes 0.000 description 1
102000055277 human IL2 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
229960000900 human factor viii Drugs 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000002743 insertional mutagenesis Methods 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
210000000107 myocyte Anatomy 0.000 description 1
101150091879 neo gene Proteins 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000002797 plasminogen activator inhibitor Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000001057 smooth muscle myoblast Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000006648 viral gene expression Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Virology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
Communication Control (AREA)
Signal Processing For Digital Recording And Reproducing (AREA)
Tyre Moulding (AREA)
Image Processing (AREA)

JP50171699A 1997-06-02 1998-06-02 スプライシング配列を含んでなる組換えアデノウイルスベクター Expired - Lifetime JP4386971B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR97/06757		1997-06-02
FR9706757A FR2763959A1 (fr)	1997-06-02	1997-06-02	Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
PCT/FR1998/001105 WO1998055639A2 (fr)	1997-06-02	1998-06-02	Vecteurs adenoviraux recombinants comprenant une sequence d'epissage

Publications (2)

Publication Number	Publication Date
JP2002511751A JP2002511751A (ja)	2002-04-16
JP4386971B2 true JP4386971B2 (ja)	2009-12-16

Family

ID=9507493

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP50171699A Expired - Lifetime JP4386971B2 (ja)	1997-06-02	1998-06-02	スプライシング配列を含んでなる組換えアデノウイルスベクター

Country Status (12)

Country	Link
US (1)	US6399587B1 (de)
EP (1)	EP0988391B1 (de)
JP (1)	JP4386971B2 (de)
AT (1)	ATE284969T1 (de)
AU (1)	AU753809B2 (de)
CA (1)	CA2292792C (de)
DE (1)	DE69828167T2 (de)
DK (1)	DK0988391T3 (de)
ES (1)	ES2232950T3 (de)
FR (1)	FR2763959A1 (de)
PT (1)	PT988391E (de)
WO (1)	WO1998055639A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200102943A (ko) *	2019-02-22	2020-09-01	알지노믹스 주식회사	암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0710288B1 (de)	1993-06-10	2006-04-05	Genetic Therapy, Inc.	Adenovirale vektoren für die behandlung der hämophilie
IL126757A0 (en) *	1998-09-07	1999-08-17	Yissum Res Dev Co	Regulation of gene expression through manipulation of mRNA splicing and its uses
EP1038959A1 (de)	1999-03-17	2000-09-27	Aventis Behring Gesellschaft mit beschränkter Haftung	Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
EP1048736A1 (de) *	1999-04-27	2000-11-02	Aventis Behring Gesellschaft mit beschränkter Haftung	DNA-Konstrukt für die Gewebespezifischen Expression eines Blutkoagulationsfaktors
EP1048726B1 (de) *	1999-04-27	2006-07-26	Négrier, Claude	Modifizierte Faktor VIII cDNA
EP1198579A1 (de) *	1999-08-06	2002-04-24	DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung	Nicht-humaner adenoviraler vektor für den gentransfer, seine anwendung und seine herstellung
US20040023292A1 (en) *	2001-10-19	2004-02-05	Mcswiggen James	Method and reagent for the detection of proteins and peptides
EP1301615A2 (de) *	2000-07-14	2003-04-16	University of Saskatchewan	Introneneinhaltende adenovirale vektoren
EP1233064A1 (de)	2001-02-09	2002-08-21	Aventis Behring Gesellschaft mit beschränkter Haftung	Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
US20030026783A1 (en) *	2001-08-03	2003-02-06	Amine Abina	Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins
EP1284290A1 (de) *	2001-08-08	2003-02-19	Aventis Behring GmbH	Erhöhung der Expression von Faktor VIII durch Insertion von spleissbaren Nukleotidsequenzen in Faktor VIII cDNA
EP1283263A1 (de) *	2001-08-08	2003-02-12	Aventis Behring GmbH	Modifizierte cDNA für die erhöhte Expression von Faktor VIII und seinen Derivaten
ITMI20012110A1 (it) *	2001-10-12	2003-04-12	Keryos Spa	Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
DE602004031681D1 (de)	2003-07-21	2011-04-14	Transgene Sa	Multifunktionelle Cytokine
ES2371175T3 (es) *	2004-10-14	2011-12-28	Crucell Holland B.V.	Vacunas de sensibilización/refuerzo de malaria.
US20090110695A1 (en) *	2006-03-27	2009-04-30	Menzo Jans Emko Havenga	Compositions Comprising a Recombinant Adenovirus and an Adjuvant
EP3587455A1 (de)	2012-10-23	2020-01-01	Emory University	Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
EP2986635B1 (de)	2013-04-18	2018-10-03	Fondazione Telethon	Effektive übertragung von grosen genen durch dual-aav-vektoren

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5518913A (en) *	1991-10-10	1996-05-21	National Research Council Of Canada	High level recombinant protein production using conditional helper-free adenovirus vector
JPH08503855A (ja) *	1992-12-03	1996-04-30	ジェンザイム・コーポレイション	嚢胞性線維症に対する遺伝子治療
DK0695157T3 (da)	1993-04-23	1999-01-18	Eliasson Torbjoern	Vandtæt dække til engangsbrug
EP0710288B1 (de) *	1993-06-10	2006-04-05	Genetic Therapy, Inc.	Adenovirale vektoren für die behandlung der hämophilie
WO1995016772A1 (en) *	1993-12-14	1995-06-22	Cornell Research Foundation, Inc.	Adenovirus gene expression system
JP3770333B2 (ja) *	1995-03-15	2006-04-26	大日本住友製薬株式会社	組換えｄｎａウイルスおよびその製造方法
EP0821739B1 (de) *	1995-04-17	2003-06-18	The Board Of Regents, The University Of Texas System	Adenovirus helfervirus system
FR2737222B1 (fr)	1995-07-24	1997-10-17	Transgene Sa	Nouveaux vecteurs viraux et lignee pour la therapie genique

1997
- 1997-06-02 FR FR9706757A patent/FR2763959A1/fr not_active Withdrawn
1998
- 1998-06-02 ES ES98928412T patent/ES2232950T3/es not_active Expired - Lifetime
- 1998-06-02 EP EP98928412A patent/EP0988391B1/de not_active Expired - Lifetime
- 1998-06-02 AU AU80247/98A patent/AU753809B2/en not_active Ceased
- 1998-06-02 PT PT98928412T patent/PT988391E/pt unknown
- 1998-06-02 CA CA2292792A patent/CA2292792C/fr not_active Expired - Fee Related
- 1998-06-02 AT AT98928412T patent/ATE284969T1/de active
- 1998-06-02 DK DK98928412T patent/DK0988391T3/da active
- 1998-06-02 US US09/445,093 patent/US6399587B1/en not_active Expired - Fee Related
- 1998-06-02 JP JP50171699A patent/JP4386971B2/ja not_active Expired - Lifetime
- 1998-06-02 WO PCT/FR1998/001105 patent/WO1998055639A2/fr not_active Ceased
- 1998-06-02 DE DE69828167T patent/DE69828167T2/de not_active Expired - Lifetime

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20200102943A (ko) *	2019-02-22	2020-09-01	알지노믹스 주식회사	암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도
KR102252423B1 (ko)	2019-02-22	2021-05-13	알지노믹스 주식회사	암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도

Also Published As

Publication number	Publication date
DK0988391T3 (da)	2005-07-25
JP2002511751A (ja)	2002-04-16
ES2232950T3 (es)	2005-06-01
CA2292792C (fr)	2010-03-30
CA2292792A1 (fr)	1998-12-10
AU753809B2 (en)	2002-10-31
EP0988391B1 (de)	2004-12-15
US6399587B1 (en)	2002-06-04
DE69828167T2 (de)	2005-12-22
PT988391E (pt)	2005-05-31
AU8024798A (en)	1998-12-21
WO1998055639A3 (fr)	1999-03-04
DE69828167D1 (de)	2005-01-20
WO1998055639A2 (fr)	1998-12-10
FR2763959A1 (fr)	1998-12-04
EP0988391A2 (de)	2000-03-29
ATE284969T1 (de)	2005-01-15

Legal Events

Date	Code	Title	Description
2005-05-12	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050418
2008-02-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080205
2008-05-29	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080507
2008-06-16	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616
2008-06-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080605
2008-07-03	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080609
2008-07-14	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080714
2009-01-13	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090113
2009-05-14	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090413
2009-06-01	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090601
2009-06-04	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090513
2009-06-22	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090622
2009-07-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090610
2009-08-21	TRDD	Decision of grant or rejection written
2009-09-01	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090901
2009-09-03	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2009-10-08	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090930
2009-10-09	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2009-10-15	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20121009 Year of fee payment: 3

Publication	Publication Date	Title
ES2246533T3 (es)	2006-02-16	Fibra adenovirica modificada y adenovirus dianas.
RU2361611C2 (ru)	2009-07-20	Конструирование рекомбинанта онколитического аденовируса, специфически экспрессирующего иммуномодуляторный фактор gm-csf в опухолевых клетках, и его применение
JP3565859B2 (ja)	2004-09-15	改良されたアデノウイルスおよびその使用法
KR100379569B1 (ko)	2004-03-06	개기원의아데노바이러스벡터및유전자치료에서이의사용방법
US6156497A (en)	2000-12-05	Recombinase-mediated generation of adenoviral vectors
US7067310B2 (en)	2006-06-27	Method for the preparation of a viral vector by inter-molecular homologous recombination
EP0696206B1 (de)	2006-08-02	Adenoviren mit veränderten faserproteinen
US6475480B1 (en)	2002-11-05	Use of adenoviral E4 reading frames to improve expression of a gene of interest
US6399587B1 (en)	2002-06-04	Recombinant adenoviral vectors comprising a splicing sequence
US7109029B2 (en)	2006-09-19	Vector constructs
JP2006345872A (ja)	2006-12-28	遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム
JPH10507061A (ja)	1998-07-14	アデノウイルス中にパッケージされたプラスミドｄｎａを用いる遺伝子送達ベクターおよびパッケージング細胞株
JPH11510049A (ja)	1999-09-07	組換えウイルスベクター製造用ヘルパーウイルス
JP2003508057A (ja)	2003-03-04	改変アデノウイルスファイバーおよび用途
US20020019051A1 (en)	2002-02-14	Chimeric adenoviral vectors
ES2239841T3 (es)	2005-10-01	Vectores adenovirales quimericos.
AU2003283504A1 (en)	2004-05-04	Recombinant adenoviral vectors and applications thereof
WO1996036365A1 (en)	1996-11-21	Gene therapy of hepatocellular carcinoma through cancer-specific gene expression
AU3345801A (en)	2001-06-21	Recombinase-mediated generation of adenoviral vectors
AU2002252061A1 (en)	2002-09-12	Vector constucts